(Q34121204)

31 July 2017

1 reference

title

HIV immunotherapeutic vaccines (English)

1 reference

31 July 2017

1 reference

B S Peters

1

1 reference

31 July 2017

publication date

1 September 2000

1 reference

Antiviral Chemistry & Chemotherapy

31 July 2017

published in

1 reference

31 July 2017

volume

11

1 reference

31 July 2017

issue

5

1 reference

31 July 2017

page(s)

311-320

1 reference

Efficacy of low-dose subcutaneous interleukin-2 to treat advanced human immunodeficiency virus type 1 in persons with </=250/microL CD4 T cells and undetectable plasma virus load

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F095632020001100501

Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. NIAID AIDS Vaccine Evaluation Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020001100501

In vivo protective anti-HIV immune responses in non-human primates through DNA immunization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020001100501

DNA vaccination as anti-human immunodeficiency virus immunotherapy in infected chimpanzees

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020001100501

Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020001100501

Detection of three distinct patterns of T helper cell dysfunction in asymptomatic, human immunodeficiency virus-seropositive patients. Independence of CD4+ cell numbers and clinical staging

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020001100501

A randomized trial of high- versus low-dose subcutaneous interleukin-2 outpatient therapy for early human immunodeficiency virus type 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020001100501

The safety and immunogenicity of a human immunodeficiency virus type 1 (HIV-1) recombinant gp160 candidate vaccine in humans. NIAID AIDS Vaccine Clinical Trials Network

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020001100501

Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020001100501

Common epitope in human immunodeficiency virus (HIV) I-GP41 and HLA class II elicits immunosuppressive autoantibodies capable of contributing to immune dysfunction in HIV I-infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020001100501

Alloimmunization as a strategy for vaccine design against HIV/AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020001100501

Safety and immunogenicity of a candidate therapeutic vaccine, p24 virus-like particle, combined with zidovudine, in asymptomatic subjects. Community HIV Research Network Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020001100501

Therapeutic potential of blocking HIV entry into cells: focus on membrane fusion inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020001100501

Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020001100501

Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: a longitudinal analysis of rapid progressors and long-term asymptomatics

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020001100501

Enhancement of human immunodeficiency virus (HIV)-specific CD4+ and CD8+ cytotoxic T-lymphocyte activities in HIV-infected asymptomatic patients given recombinant gp160 vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020001100501

Comparison of subcutaneous and intravenous interleukin-2 in asymptomatic HIV-1 infection: a randomised controlled trial. ANRS 048 study group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020001100501

Mother-child class I HLA concordance increases perinatal human immunodeficiency virus type 1 transmission

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020001100501

Phenotypic analysis of human immunodeficiency virus (HIV) type 1 cell-mediated immune responses after treatment with an HIV-1 immunogen

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020001100501

Immune response in human melanoma after transfer of an allogeneic class I major histocompatibility complex gene with DNA-liposome complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020001100501

Semiallogeneic cell hybrids as therapeutic vaccines for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020001100501

Studies in subjects with long-term nonprogressive human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020001100501

A pilot phase II study of the safety and immunogenicity of HIV p17/p24:VLP (p24-VLP) in asymptomatic HIV seropositive subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020001100501

Phase II controlled trial of post-exposure immunization with recombinant gp160 versus antiretroviral therapy in asymptomatic HIV-1-infected adults. VaxSyn Protocol Team

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020001100501

A phase I evaluation of the safety and immunogenicity of vaccination with recombinant gp160 in patients with early human immunodeficiency virus infection. Military Medical Consortium for Applied Retroviral Research

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020001100501

HTLV-III-neutralizing antibodies in patients with AIDS and AIDS-related complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020001100501

Safety and immunogenicity of a live recombinant canarypox virus expressing HIV type 1 gp120 MN MN tm/gag/protease LAI (ALVAC-HIV, vCP205) followed by a p24E-V3 MN synthetic peptide (CLTB-36) administered in healthy volunteers at low risk for HIV inf

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020001100501

Immunization with recombinant p17/p24:Ty virus-like particles in human immunodeficiency virus-infected persons

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020001100501

Allo-immunization elicits CD8+ T cell-derived chemokines, HIV suppressor factors and resistance to HIV infection in women

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020001100501

Active Immunization of Patients with HIV Infection: A Study of the Effect of VaxSyn, a Recombinant HIV Envelope Subunit Vaccine, on Progression of Immunodeficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020001100501

Anti-cell antibody in macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020001100501

10.1177/095632020001100501

21 January 2018

Identifiers

DOI

1 reference

31 July 2017

1 reference